In some mouse tumor models, the therapeutic effects of IL-2-based treatment only manifest in combination with immunogenic chemotherapy (B16F10 melanoma in C57BL/6 mice and BCL1 leukemia in BALB/C mice) [3] or irradiation (K5L1940 adenocarcinoma in C57BL/6 mice) [10]. This evidence concerns the gene IL2 and neoplasm.